Skip to content
Austin Top 50
Author:
Racura Oncology Limited
Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer
October 12, 2026
Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer
June 25, 2026